| Ytd | -64.23% | |
| 1y | -94.39% |
| Open | 0.24 | Prev Close | 0.25 | Low | 0.24 | High | 0.24 | Mkt Cap | 10.48M |
| Vol | 404.87K | Avg Vol | 12.36M | EPS | -1.66 | P/E | N/A | Forward P/E | -1.49 |
| Beta | 0.33 | Short Ratio | 1.69 | Inst. Own | 53.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.26 | 200-d Avg | 0.49 | 1yr Est | 13.00 |
VTGN News
Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday'
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentatio
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regula
Vistagen Inc. (NASDAQ:VTGN) surged on Wednesday after preliminary findings from the open-label exten
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anx
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market sessi
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REI
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-
Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study particip
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally sta
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Effi
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clini
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in S
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fased
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YO
NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is invest
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical comp
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar